NIH Highlighted Topic: Improving Diagnostic Safety and Quality in Healthcare
Below is a brief summary. Please check the full solicitation before applying (link in resources section).
Executive Summary:
The National Institutes of Health (NIH) is encouraging research that closes critical gaps in diagnostic safety and quality, particularly diagnostic failures that contribute to patient harm. The topic prioritizes three strategic areas: technology and innovation, infrastructure and system design, and advancing the science of diagnosis.
On the technology side, NIH highlights AI-enabled tools including large language models, telehealth and other digital health solutions, point-of-care diagnostic testing, enhanced data sources, sensors, and analytic methods, and other novel diagnostic tests. System-level priorities include coordinating care across the full diagnostic trajectory, integrating clinical tools with patient-reported information, and improving communication among patients, clinicians, and care teams.
NIBIB, the lead institute, focuses on technologies with broad applicability, such as AI to improve point-of-care imaging quality, motion correction for radiological imaging, 3D-printed phantoms, AI surveillance of diagnostic errors, workflow platforms that reduce diagnostic delays, and VR and AR visualization tools. NCI seeks faster, more accurate cancer diagnosis, including rare and early-onset cancers and quicker follow-up after abnormal screening results. NIDA is interested in AI, digital biomarkers, and neuroimaging for detecting substance use disorder and related conditions.
How to apply: This is a Highlighted Topic rather than a standalone NOFO, so it has no dedicated solicitation or deadline of its own. Small businesses should apply through the NIH SBIR omnibus (PA-27-100) or STTR omnibus (PA-27-102) and reference this Highlighted Topic by name in the Specific Aims or Significance section so program staff can connect the application to this priority. We also recommend contacting the central NIBIB scientific contact or the relevant institute contact to confirm fit before writing.
This highlighted topic is led by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) with participation from NCI, NIDA, NIDCR, and the Office of Behavioral and Social Sciences Research (OBSSR). NIDCR notes it may give special consideration to meritorious applications in this area. The topic is active from July 28, 2026 through July 28, 2028.
How much funding would I receive?
Awards provide up to $323,090 for Phase I projects (up to 2 years) and $2,153,927 for Phase II projects (up to 3 years). Some topics approved by NIH may exceed these limits. Fast-Track and Phase IIB (follow-on) options allow continuous or extended funding beyond Phase II.
What could I use the funding for?
Funding may support the research, development, validation, and commercialization of diagnostic technologies and workflow tools that reduce diagnostic errors and delays.
Eligible activities may include:
AI and large language model tools for diagnostic decision support and error surveillance
Point-of-care diagnostic tests and imaging quality enhancements
Motion correction, phantom, and advanced visualization technologies for radiology
Workflow and reporting platforms that close the loop on abnormal test results
Telehealth and digital health diagnostic solutions
Clinical validation studies using real-world data
Regulatory strategy, commercialization planning, and market validation
Funding may also support personnel, materials and supplies, equipment, contract research, academic collaborations, intellectual property protection, and commercialization activities necessary to advance a scalable and commercially viable diagnostic product aligned with NIH priorities.
Are there any additional benefits I would receive?
Beyond the formal funding award, awardees gain several strategic advantages:
Government Validation and Credibility:
Being selected for an NIH-backed SBIR grant signals technical excellence and alignment with national health and biomedical priorities. This validation builds investor and partner confidence.Enhanced Visibility and Market Recognition:
Awardees are featured in NIH and HHS announcements, helping attract partnerships, media attention, and future contracting opportunities.Access to the Federal Innovation Ecosystem:
Recipients join a national network of researchers and agencies advancing life science innovation, often opening doors to collaborations with NIH laboratories and federal health programs.Stronger Commercial and Exit Potential:
By maturing technology through nondilutive funding, companies strengthen valuation, de-risk commercialization, and increase attractiveness for acquisition or follow-on private investment.
What is the timeline to apply and when would I receive funding?
Applications are accepted each year on January 5th, April 5th, and September 5th. The next standard deadline is January 5, 2027. This Highlighted Topic remains active until July 28, 2028. Funding is received approximately 9 months after submission.
Where does this funding come from?
Funding comes from the U.S. Department of Health and Human Services, with statutory set-asides requiring NIH, CDC, and FDA to devote portions of their extramural R&D budgets (3.2% for SBIR, 0.45% for STTR) to support small business innovation.
Who is eligible to apply?
Applicants must be U.S. small business concerns (SBCs) that:
Are organized for profit with a U.S. place of business.
Have 500 or fewer employees including affiliates.
Are more than 50% owned by U.S. citizens or permanent residents, qualifying U.S. entities, or combinations thereof.
What companies and projects are likely to win?
Projects that demonstrate:
A clear unmet medical or public-health need,
Strong scientific rationale and feasibility,
High commercialization potential, supported by a realistic market and regulatory strategy, and
Alignment with an NIH Institute's specific research mission, including an explicit connection to this Highlighted Topic.
Competitive applicants often have an early prototype, preliminary data, and a defined path to market adoption.
Are there any restrictions I should know about?
Companies must complete multiple federal registrations (SAM.gov, Grants.gov, eRA Commons, SBA Company Registry) before applying.
Foreign entities are not eligible.
Disclosure of foreign affiliations and compliance with national security screening are mandatory. Currently we do not recommend any sort of foreign affiliation.
How long will it take me to prepare an application?
For a first-time applicant, preparing a competitive submission will likely take 120 to 200 hours in total.
How can BW&CO help?
Our team specializes in complex federal R&D proposals and can:
Triple your likelihood of success through proven strategy and insider-aligned proposal development
Reduce your time spent on the proposal by 50 to 80%, letting your team focus on technology and operations
Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth.